Association between low serum magnesium level and major adverse cardiac events in patients treated with drug-eluting stents for acute myocardial infarction

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  An, Guipeng ^a   Du, Zhongqi ^a   Meng, Xiao ^a   Guo, Tao ^a   Shang, Rui ^a   Li, Jifu ^a   An, Fengshuang ^a   Li, Wenjing ^b   Zhang, Cheng ^a  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MAGNESIUM;

ACUTE HEART INFARCTION; ADULT; ARTICLE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CLINICAL EVALUATION; DEATH; DEVICE THERAPY; DISEASE ASSOCIATION; DRUG ELUTING STENT; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; HEART DISEASE; HEART INFARCTION; HUMAN; INCIDENCE; MAGNESIUM BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PREDICTION; REVASCULARIZATION; RISK ASSESSMENT; ACUTE DISEASE; ADVERSE EFFECTS; BLOOD; CARDIOVASCULAR DISEASES; MIDDLE AGED; MORTALITY; MYOCARDIAL INFARCTION; PATHOPHYSIOLOGY; PERCUTANEOUS CORONARY INTERVENTION; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; SURVIVAL RATE; UNSTABLE ANGINA PECTORIS;

ACUTE DISEASE; ADULT; ANGINA, UNSTABLE; CARDIOVASCULAR DISEASES; DRUG-ELUTING STENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MAGNESIUM; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SURVIVAL RATE;

EID: 84902530515     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0098971     Document Type: Article

References (30)

1. Kirtane AJ, Gupta A, Iyengar S, Moses JW, Leon MB, et al. (2009) Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies. Circulation 119: 3198-3206.
2. Roukoz H, Bavry AA, Sarkees ML, Mood GR, Kumbhani DJ, et al. (2009) Comprehensive meta-analysis on drug-eluting stents versus bare-metal stents during extended follow-up. Am J Med 122: 581 e581-510.
3. Ishikawa K, Aoyama Y, Hirayama H (2012) Management of drug-eluting stent restenosis. J Invasive Cardiol 24: 178-182.
4. Luscher TF, Steffel J, Eberli FR, Joner M, Nakazawa G, et al. (2007) Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation 115: 1051-1058. (Pubitemid 46328299)
5. Chakraborti S, Chakraborti T, Mandal M, Mandal A, Das S, et al. (2002) Protective role of magnesium in cardiovascular diseases: a review. Mol Cell Biochem 238: 163-179. (Pubitemid 35023539)
6. Gartside PS, Glueck CJ (1995) The important role of modifiable dietary and behavioral characteristics in the causation and prevention of coronary heart disease hospitalization and mortality: the prospective NHANES I follow-up study. J Am Coll Nutr 14: 71-79.
7. Ford ES (1999) Serum magnesium and ischaemic heart disease: findings from a national sample of US adults. Int J Epidemiol 28: 645-651.
8. Reffelmann T, Ittermann T, Dorr M, Volzke H, Reinthaler M, et al. (2011) Low serum magnesium concentrations predict cardiovascular and all-cause mortality. Atherosclerosis 219: 280-284.
9. Dasgupta A, Sarma D, Saikia UK (2012) Hypomagnesemia in type 2 diabetes mellitus. Indian J Endocrinol Metab 16: 1000-1003.
10. Lima Mde L, Cruz T, Rodrigues LE, Bomfim O, Melo J, et al. (2009) Serum and intracellular magnesium deficiency in patients with metabolic syndrome-evidences for its relation to insulin resistance. Diabetes Res Clin Pract 83: 257-262.
11. Qin SY, Zhou Y, Jiang HX, Hu BL, Tao L, et al. (2013) The association of diabetes mellitus with clinical outcomes after coronary stenting: a meta-analysis. PLoS One 8: e72710.
12. Cojocaru IM, Cojocaru M, Burcin C, Atanasiu NA (2007) Serum magnesium in patients with acute ischemic stroke. Rom J Intern Med 45: 269-273.
13. Shechter M, Merz CN, Rude RK, Paul Labrador MJ, Meisel SR, et al. (2000) Low intracellular magnesium levels promote platelet-dependent thrombosis in patients with coronary artery disease. Am Heart J 140: 212-218. (Pubitemid 30641580)
14. Roth A, Eshchar Y, Keren G, Kerbel S, Harsat A, et al. (1994) Effect of magnesium on restenosis after percutaneous transluminal coronary angioplasty: a clinical and angiographic evaluation in a randomized patient population. A pilot study. The Ichilov Magnesium Study Group. Eur Heart J 15: 1164-1173. (Pubitemid 124005603)
15. Pereira JN, Rabacal C, Laires MJ, Pereira T, Fernandes JS, et al. (1988) Serum and red blood cell Mg levels in acute coronary events. Magnesium 7: 9-15. (Pubitemid 18096887)
16. Rasmussen HS, Aurup P, Hojberg S, Jensen EK, McNair P (1986) Magnesium and acute myocardial infarction. Transient hypomagnesemia not induced by renal magnesium loss in patients with acute myocardial infarction. Arch Intern Med 146: 872-874. (Pubitemid 16116662)
17. Pollak A, Rokach A, Blumenfeld A, Rosen LJ, Resnik L, et al. (2004) Association of oestrogen receptor alpha gene polymorphism with the angiographic extent of coronary artery disease. Eur Heart J 25: 240-245. (Pubitemid 38235161)
18. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, et al. (2012) Third universal definition of myocardial infarction. Circulation 126: 2020-2035.
19. Shivakumar K (2001) Model of cardiovascular injury in magnesium deficiency. Med Hypotheses 56: 110-113.
20. Sherer Y, Bitzur R, Cohen H, Shaish A, Varon D, et al. (2001) Mechanisms of action of the anti-atherogenic effect of magnesium: lessons from a mouse model. Magnes Res 14: 173-179. (Pubitemid 33644675)
21. Dong JY, Xun P, He K, Qin LQ (2011) Magnesium intake and risk of type 2 diabetes: meta-analysis of prospective cohort studies. Diabetes Care 34: 2116-2122.
22. Morrill GA, Gupta RK, Kostellow AB, Ma GY, Zhang A, et al. (1997) Mg2+ modulates membrane lipids in vascular smooth muscle: a link to atherogenesis. FEBS Lett 408: 191-194. (Pubitemid 27226794)
23. Fiset C, Kargacin ME, Kondo CS, Lester WM, Duff HJ (1996) Hypomagnesemia: characterization of a model of sudden cardiac death. J Am Coll Cardiol 27: 1771-1776. (Pubitemid 26198033)
24. Khan AM, Lubitz SA, Sullivan LM, Sun JX, Levy D, et al. (2013) Low serum magnesium and the development of atrial fibrillation in the community: the Framingham Heart Study. Circulation 127: 33-38.
25. Peacock JM, Ohira T, Post W, Sotoodehnia N, Rosamond W, et al. (2010) Serum magnesium and risk of sudden cardiac death in the Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J 160: 464-470.
26. Shechter M, Sharir M, Labrador MJ, Forrester J, Silver B, et al. (2000) Oral magnesium therapy improves endothelial function in patients with coronary artery disease. Circulation 102: 2353-2358.
27. Amighi J, Sabeti S, Schlager O, Mlekusch W, Exner M, et al. (2004) Low serum magnesium predicts neurological events in patients with advanced atherosclerosis. Stroke 35: 22-27. (Pubitemid 38057583)
28. Shechter M, Merz CN, Paul-Labrador M, Meisel SR, Rude RK, et al. (1999) Oral magnesium supplementation inhibits platelet-dependent thrombosis in patients with coronary artery disease. Am J Cardiol 84: 152-156. (Pubitemid 29331330)
29. Ravn HB, Kristensen SD, Vissinger H, Husted SE (1996) Magnesium inhibits human platelets. Blood Coagul Fibrinolysis 7: 241-244. (Pubitemid 26171539)
30. Sternberg K, Gratz M, Koeck K, Mostertz J, Begunk R, et al. (2012) Magnesium used in bioabsorbable stents controls smooth muscle cell proliferation and stimulates endothelial cells in vitro. J Biomed Mater Res B Appl Biomater 100: 41-50.